Preview Newsletter
XARELTO Media Monitoring – Week of 5-6-16
-
Xarelto Lawsuit Requests $4.35 Million Following Alleged Severe Bleeding Episode
Apr 29, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com discusses information from yet another Xarelto-related lawsuit filed against manufacturers Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation), as well as multiple other defendants. The plaintiff filing the lawsuit alleges that use of the new-generation blood-thinning drug caused him to suffer from an unexpected and severe bleeding event. -
Xarelto Lawsuit Plaintiffs Scheduled To See Bellwether Trial Hearings In Early 2017
Apr 29, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the scheduled bellwether lawsuit trials for lawsuits consolidated in Xarelto multidistrict litigation number 2592. Bellwether trials will hear 4 cases chosen from a bellwether pool of 40 which are intended to best represent all plaintiffs who have currently filed Xarelto-related lawsuits. -
Xarelto Risk of Bleeding
Apr 29, 2016 | Top Class Actions
By Tamara Burns
Xarelto (rivaroxaban) is a medication used to prevent clots in the blood, otherwise known as an anticoagulant or blood thinner. It has been on the market since 2008 and is manufactured by Bayer. -
NC Woman Files Xarelto Side Effects Lawsuit
May 4, 2016 | RightingInjustice
By Jennifer-Walker Journey
A North Carolina woman has filed a lawsuit against the makers of the blood thinner Xarelto claiming the drug companies failed to adequately warn of Xarelto side effects, which she says ultimately led to the death of her husband. -
PA Man Files Xarelto Lawsuit Citing Serious Bleeding Risks
May 4, 2016 | RightingInjustice
By Jennifer Walker-Journey
A Pennsylvania man is suing Johnson & Johnson’s Janssen Pharmaceuticals, Bayer Healthcare, and their related companies over claims that the companies’ blood thinner Xarelto caused him serious life threatening injuries. -
Side Effects & Adverse Reactions
May 3, 2016 | Recall Guide
The U.S. Food and Drug Administration-approved labeling for XARELTO (rivaroxaban) contains the following warnings and precautions -
Second J&J Talcum Powder Lawsuit Verdict Affirms Dangers, Signals More Litigation
May 5, 2016 | Nager, Romaine & Schneiberg, Co.
n a recent blog post, we alerted you to a civil suit that found corporate giant Johnson & Johnson (J&J) liable for an Alabama woman’s ovarian cancer—a cancer which she claimed in the lawsuit resulted from using J&J’s Baby Powder and Shower to Shower powder, both of which contain talcum powder. -
Man files Xarelto Subdural Hematoma Lawsuit
May 5, 2016 | Miller Legal LLP
A man recently filed a personal injury lawsuit against drug manufacturers Bayer and the Janssen unit of Johnson & Johnson based on claims that he suffered severe and near-fatal injuries after using their drug Xarelto. -
What are Common Xarelto Bleeding Symptoms?
May 6, 2016 | Johnston Law Group
Common Xarelto bleeding symptoms may go unnoticed for some time, as is the case with certain internal bleeding wounds, or may be clearly indicated by intense pain and hemorrhaging. Taking certain drugs at the same time as Xarelto, such non-steroidal anti-inflammatory drugs or aspirin, increases the risk of bleeding.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Full Text of Stories Below
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
-
Xarelto Lawsuit Requests $4.35 Million Following Alleged Severe Bleeding Episode
Apr 29, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com discusses information from yet another Xarelto-related lawsuit filed against manufacturers Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation), as well as multiple other defendants. The plaintiff filing the lawsuit alleges that use of the new-generation blood-thinning drug caused him to suffer from an unexpected and severe bleeding event. His lawsuit was transferred to be consolidated with thousands of others in a move by the U.S. Judicial Panel on Multidistrict Litigation, forming MDL 2592. Today, MDL 2592 involves over 2,800 complaints which all commonly allege the dangers of Xarelto. The cases are being overseen in Eastern Louisiana by Judge Eldon E. Fallon.
This lawsuit is especially notable as it involves 90-counts and requests a large monetary compensation: $4.35 million. The plaintiff alleges that defendants purposefully marketed Xarelto in misleading ways to display it as both safe and effective, while neglecting to properly address potential dangerous side effects which have been linked to its use. Other plaintiffs have also drawn attention to Xarelto marketing tactics, and have noted the use of celebrity endorsements and potentially misleading information.
This lawsuit plaintiff, however, addresses the fact that the drug’s manufacturers had likely been previously aware that their drug could cause serious bleeding risks for patients using it, and he offers supporting evidence for this case. The man noted, “Defendants use the results of the Rocket AF study, the Record studies, and the Einstein studies to promote Xarelto in their promotional materials, including the Xarelto website, which tout the positive results of those studies. However, defendants’ promotional materials fail to similarly highlight the increased risk of gastrointestinal bleeding and bleeding that required transfusion among other serious bleeding concerns.”
Similar allegations surrounding Xarelto have been made through adverse event reports to the FDA, and additional controversies surrounding the FDA’s approval of the drug have recently spawned an investigation by European Regulators. Prior information has shown that Xarelto manufacturers spent over $11 million to promote the drug, and that their tactics brought in an estimated $582 million in revenue in the drug’s first year on the market alone. Xarelto was approved and released to market just 5 years ago, in 2011, and has since become the subject of more than 3,400 lawsuits from across America. Lawsuits concerning the drug have now been filed in Canada as well.
Attorney Joseph Osborne is working to help other patients who have used Xarelto and who feel that the drug has negatively impacted their health. He wants to ensure that all affected patients will be given an opportunity to fully investigate their legal rights in the matter, as they could be entitled to significant compensation. To help patients desiring to learn more about their legal options, Attorney Osborne is now offering free legal consultations for qualified parties.
To request additional information, or to ask questions, please contact Attorney Osborne by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2922094#ixzz47syaSOTd
-
Xarelto Lawsuit Plaintiffs Scheduled To See Bellwether Trial Hearings In Early 2017
Apr 29, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the scheduled bellwether lawsuit trials for lawsuits consolidated in Xarelto multidistrict litigation number 2592. Bellwether trials will hear 4 cases chosen from a bellwether pool of 40 which are intended to best represent all plaintiffs who have currently filed Xarelto-related lawsuits. The hearings are intended to provide all involved with a better idea of how juries might react to certain pieces of evidence and testimony moving forward. Lawsuits involved in MDL 2592 currently number over 2,800 and are being overseen in Eastern Louisiana by the Honorable Judge Eldon Fallon. They share strikingly similar plaintiff allegations made against defendants Bayer AG and Johnson & Johnson’s subsidiary company Janssen Pharmaceuticals.
In 2011, Xarelto launched onto the market after gaining approval by the U.S. Food and Drug Administration. The drug was a revolutionary, new-generation blood thinner which was able to provide patients with freedoms that other blood thinners had been unable to. Unlike traditional blood thinners, Xarelto required no special diets, dosage adjustments, or regular monitoring and check-ins with a physician. It also, however, was released to market with no corresponding antidote; a dangerous move that many plaintiffs today call recklessly negligent.
Xarelto remained on the market without any antidote for over 4 years, according to reports. Patients taking the drug, therefore, had to be very careful of being injured while on it, which is sometimes hard to avoid. Without an antidote to clot the blood and counter the effects of Xarelto, even a minor injury could become life-threatening due to blood loss. Traditional blood thinners offer a corresponding antidote through vitamin K. When patients using these blood thinners injure themselves and begin to bleed, doctors are able to counter the blood thinner’s effects with vitamin K and clot their blood, potentially saving their lives.
Since this time, Xarelto has been linked to increased risk of serious and potentially fatal bleeding events by the thousands of plaintiffs filing lawsuits. As these plaintiffs await trial dates, Attorney Joseph Osborne is working to help other patients who have used Xarelto and who feel that the drug has caused them to suffer from health complications. Those affected may be entitled to substantial compensation gained through legal action, and are encouraged to take the opportunity to explore their legal rights in the matter fully. Those who wish to look into their options further are offered complimentary legal consultations at this time from Attorney Osborne.
To request additional information, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.wflx.com/story/31853895/xarelto-lawsuit-plaintiffs-scheduled-to-see-bellwether-trial-hearings-in-early-2017
-
Apr 29, 2016 | Top Class Actions
By Tamara Burns
Xarelto (rivaroxaban) is a medication used to prevent clots in the blood, otherwise known as an anticoagulant or blood thinner. It has been on the market since 2008 and is manufactured by Bayer.
As with any over-the-counter or prescription medication, side effects are common with the use of drugs. Many times the side effects are mild and may wane and disappear once the body adjusts to the medication. In other cases, the side effects experienced by patients can be severe – or even fatal.
Xarelto Side Effects
With Xarelto, the following side effects are common and are usually mild in nature, and may reduce or disappear with continued use:
Itching
Back painHeadache
Pain in the extremities
Muscle pain or spasm
Lightheadedness or fainting
One of the most dangerous Xarelto side effects is internal bleeding. Because Xarelto’s method of action involves the drug inhibiting the body’s natural clotting mechanism, any patient can be at risk for increased internal bleeding. A patient may have had no issues with bruising or internal bleeding in the past, but may experience these Xarelto problems on the medication.
Internal bleeding may be difficult to determine at first since the site of the bleeding cannot be visualized. Most often, internal bleeding as a result of Xarelto side effects is located in the gastrointestinal tract or in the brain.
The following signs and symptoms indicate the possibility of internal bleeding Xarelto side effects:
Red, black or tarry stools
Vomiting up a substance that resembles coffee grounds
Red or dark brown urine
Bruising
Unusual pain
Confusion
Dizziness
Low blood pressure
Weakness
Loss of coordination or balance
Vision difficulties
Slurring of speech
Extreme sleepiness or loss of consciousness
With an older anticoagulant drug that was a staple for six decades, warfarin, there was an antidote to reverse bleeding. Patients could have fresh frozen plasma and intravenous vitamin K administered to stop the bleed.
However, with Xarelto, there is no antidote, and if the bleeding is too severe despite emergency intervention, the bleeding can be fatal.
Xarelto Internal Bleeding Lawsuits
Lawsuits against Xarelto’s manufacturer, Bayer, are so numerous that they have all been consolidated into a multidistrict litigation (MDL) to address the allegations.
In an MDL, the lawsuits are all set to a single court under a single judge so that pretrial discovery may be streamlined. A small group of cases are then selected as “bellwether” cases to represent the group to see how the proceedings will play out.
Such a process allows for non-duplicative discovery and allows the cases to have similar rulings and outcomes.
In the Xarelto MDL, there are over 3,000 cases currently pending in the U.S. District Court for the Eastern District of Louisiana with trials set to begin in August of this year.
These lawsuits generally allege that Bayer negligently and fraudulently misrepresented the product, breached warranties, and violated consumer protection laws and seek damages for medical expenses, loss of spousal companionship, lost wages and earning capacity and more.
If you or someone you loved experienced internal bleeding Xarelto side effects or other Xarelto problems, you may be eligible to file a lawsuit. An experienced Xarelto attorney can review your case at no charge and can explain your legal options to you.
https://topclassactions.com/lawsuit-settlements/lawsuit-news/333832-xarelto-risk-bleeding/
-
NC Woman Files Xarelto Side Effects Lawsuit
May 4, 2016 | RightingInjustice
By Jennifer-Walker Journey
A North Carolina woman has filed a lawsuit against the makers of the blood thinner Xarelto claiming the drug companies failed to adequately warn of Xarelto side effects, which she says ultimately led to the death of her husband.
Betty Moses filed the lawsuit on behalf of the estate of her husband, Larry Moses, on April 4 in the U.S. District Court for the Eastern District of Louisiana against Janssen Research & Development LLC, Janssen Ortho LLL, Janssen Pharmaceuticals Inc., Johnson & Johnson Co., Bayer Pharma AG, Bayer Corp.,Bayer Healthcare Pharmaceuticals Inc., Bayer Healthcare AG, and Bayer AG. The lawsuit cites manufacturing defect, design defect, negligence, wrongful death and other counts.
According to the complaint, Larry Moses took Xarelto from Nov. 6, 2013, to April 14, 2014, during which he suffered serious and dangerous bleeding event. He ultimately died from his injuries on June 19, 2014.
Xarelto is from a new class of blood thinners designed as a more convenient alternative to the long-used warfarin. The drug is prescribed to prevent strokes in patients with atrial fibrillation, to prevent or treat deep vein thrombosis and pulmonary embolism, and to prevent blood clots in patients who have recently undergone knee or hip replacement surgery.
Both warfarin and Xarelto, as well as other blood thinners, increase the risk for bleeding events including gastrointestinal bleeds, brain hemorrhages and bleeding deaths. Unlike warfarin, there is no antidote to reverse the blood thinning effects of Xarelto in the event of a bleeding emergency. As a result, hundreds of lawsuits, like the Moses’, have been filed againstJanssen and Bayer alleging the companies did not adequately test the drug nor warn the public of potential side effects.
http://www.rightinginjustice.com/news/2016/05/05/nc-woman-files-xarelto-side-effects-lawsuit/
-
PA Man Files Xarelto Lawsuit Citing Serious Bleeding Risks
May 4, 2016 | RightingInjustice
By Jennifer Walker-Journey
A Pennsylvania man is suing Johnson & Johnson’s Janssen Pharmaceuticals, Bayer Healthcare, and their related companies over claims that the companies’ blood thinner Xarelto caused him serious life threatening injuries.
David Blair filed a complaint in the U.S. District Court for the Eastern District ofLouisiana naming Janssen Research & Development LLC, Janssen Ortho LLL,Janssen Pharmaceuticals Inc., Johnson & Johnson Co., Bayer Pharma AG, Bayer Corp., Bayer Healthcare Pharmaceuticals Inc., Bayer Healthcare LLC, Bayer Healthcare AG and Bayer AG. The lawsuit cites alleged fraud, design defect, manufacturing defect, failure to warn, breach of express and implied warranty, and negligent misrepresentation.
Blair claims that he began treatment with Xarelto in February 2014. In April 2014, he suffered gastrointestinal bleeding, rectal bleeding and anemia, for which he needed to be hospitalized. He claims his injuries caused him pain and suffering, permanent injury, mental anguish, diminished enjoyment of life, and financial expenses for hospitalization and medical care.
Xarelto was approved in 2011. It is in a new class of blood thinners designed to go head-to-head with the long-used warfarin. It is indicated for the prevention of stroke in patients with atrial fibrillation, the treatment and prevention of deep vein thrombosis and pulmonary embolism, and for the prevention of blood clots in patients who have recently undergone hip or knee replacement surgery .
Xarelto is considered more convenient than warfarin because it has fewer dietary restrictions and drug interactions, with a similar efficacy profile. Like warfarin and other blood thinners, Xarelto can cause serious bleeding events including gastrointestinal and rectal bleeds, brain bleeds, and bleeding deaths. Unlike warfarin, there is no antidote to revers the bleeding effects of Xarelto in the event of a bleeding emergency.
Blair’s lawsuit is one of hundreds waged against the drug companies citing failure to warn and other claims.
http://www.rightinginjustice.com/news/2016/05/04/pa-man-files-xarelto-lawsuit-citing-serious-bleeding-risks/
-
Side Effects & Adverse Reactions
May 3, 2016 | Recall Guide
The U.S. Food and Drug Administration-approved labeling for XARELTO (rivaroxaban) contains the following warnings and precautions:
1. Increased risk of thrombotic events after premature discontinuation.
A patient should not stop taking XARELTO or any anticoagulant pill unless an adequate alternative medication has been prescribed, the patient has completed prescribed therapy or the patient is suffering from a serious and potentially fatal bleeding episode. It should be noted that, in clinical trials involving patients with nonvalvular atrial fibrillation, an increased risk of stroke was observed as patients switched from XARELTO to warfarin.
2. Risk of bleeding.
XARELTO raises the risk of serious and potentially fatal bleeding events. In clinical trials, bleeding complications were the most commonly reported adverse reaction. A hemorrhage, or bleeding from ruptured blood vessels, is a type of a bleeding complication that can lead to stroke or death. The bleeding events reported in XARELTO clinical trials include:
Intracranial hemorrhage ñ Bleeding within the skull, or cranium, which may lead to brain cell/nerve damage, stroke or death. †Headaches, blurred vision, slurred speech, confusion and feelings of numbness, tingling or loss of control of one side of the body or face are signs of intracranial bleeding. Most XARELTO bleeding events involve this type of bleeding.
Intraspinal hemorrhage ñ Bleeding within the spinal cord may lead to paralysis. A patient using XARELTO should seek medical help if he or she experiences weakness or loss of sensation in the limbs or experiences difficulties with urination.
Gastrointestinal bleeding ñ Bleeding may occur in the upper (esophagus, stomach, upper portion of small intestine) or lower (large intestine, anus, rectum, bowels and lower portion of the small intestine) GI tracts. Signs of this bleeding include blood in the stool or urine, dark (tar-like) stool or vomiting blood (which looks like coffee grounds).
Other types of bleeding events reported among XARELTO users in clinical trials are:
Intraocular (eye)
Pericardial (tissue surrounding the heart)
Intra-articular (joints)
Intramuscular (muscles)
Retroperitoneal (abdomen).
There is no known antidote for XARELTO-related bleeding events such as the administration of vitamin K or protamine sulfate. A patient may need to wait between 5 to 9 hours for the medication to pass through oneís system. A doctor may order blood replacement, or a transfusion.
3. Spinal/epidural anesthesia or puncture.
Pooling of blood (hematoma) may occur when spinal or epidural anesthesia is administered to a patient who is using XARELTO. The result may be long-term or permanent paralysis. For this reason, use of the anesthesia or the use of an epidural catheter should only take place when the anticoagulant effect of XARELTO is at its lowest. Also, a patient should be closely monitored for complications that include:Back painNumbness, tingling or weakness in the lower limbsLoss of bowel or bladder function.
If a spinal or epidural hematoma occurs, emergency treatment may be needed such as spinal decompression surgery, which will relieve pressure on the spine.
4. Use in patients with renal impairment.
The use of an anticoagulant such as XARELTO is a concern with a patient suffering from renal impairment due to the fact that a patient may experience a loss of kidney function (or the filtering of waste products from the blood). Acute renal failure may be fatal.
5. Use in patients with hepatic impairment.
A patient ís risk of experiencing a severe and potentially deadly bleeding episode while using XARELTO may be increased if the patient suffers from reduced functioning of the liver.
6. Use with P-gp and strong CYP3A4 inhibitors or inducers.
XARELTO should not be used by patients who are also taking medications that either reduce or increase certain enzymes, including:
Ketoconazole and itraconazole (commonly prescribed antifungal medications)
Lopinavir/ritonavir (a drug used to treat HIV infection)
Conivaptan (a medication used to treat low blood sodium levels)
Carbamazepine and phenytoin (anti-convulsants)
Rifampin (a tuberculosis medication)
St. Johnís wort (an herb often taken to treat depression).
7. Risk of pregnancy-related hemorrhage.
Doctors should fully weight the potential benefits of XARELTO use by pregnant women against the possible risks to the mother and fetus. In particular, the anticoagulant effect of XARELTO cannot be monitored through standard lab tests, and risks of severe bleeding may arise due to the inability to reverse the drugís anticoagulant effect.
Patients with prosthetic heart valves.
The FDA has approved the use of XARELTO for the treatment of patients with non-heart valve-related atrial fibrillation. The manufacturer warns that no study has been undertaken of how XARELTO affects patients with artificial heart valves.
9. Acute pulmonary embolism in hemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.
XARELTO should not be administered to a patient with a blood clot in the lungs who is experiencing a significant drop in blood pressure and who will undergo emergency treatment for the condition. Sponsored by: Salvi, Schostok & Pritchard P.C.
https://www.recallguide.org/drug/xarelto/
-
Second J&J Talcum Powder Lawsuit Verdict Affirms Dangers, Signals More Litigation
May 5, 2016 | Nager, Romaine & Schneiberg, Co.
In a recent blog post, we alerted you to a civil suit that found corporate giant Johnson & Johnson (J&J) liable for an Alabama woman’s ovarian cancer—a cancer which she claimed in the lawsuit resulted from using J&J’s Baby Powder and Shower to Shower powder, both of which contain talcum powder.
Now, on Monday, May 2, a U.S. jury in a Missouri court has ordered J&J to pay $55 million to a 62-year-old South Dakota woman who stated that she too got ovarian cancer from using J&J’s talcum powder products. This is the second time in 2016 that J&J has lost a trial in which its talc-based products were accused of causing cancer.
Background
In this latest trial, Gloria Ristesund was awarded $5 million for compensation and another $50 million in punitive damages by state court jurors in St. Louis. Ristesund was diagnosed with cancer in 2011, which she stated was “a direct and proximate result of the unreasonably dangerous and defective nature of talcum powder,” for nearly 40 years of her life. Ristesund underwent a hysterectomy and related surgeries, and her cancer is thankfully currently in remission.
Currently, more than 1,200 civil suits are active against J&J alleging inadequate warnings about cancer risks for its talcum-containing products – most notably, its signature Baby Powder and Shower to Shower. In Ristesund’s case, the trial took only three weeks, and jurors deliberated for no more than a day, before the verdict was returned in her favor. J&J is planning to appeal the verdict.
In the earlier 2016 verdict against J&J, Jackie Fox, of Birmingham, Alabama, was diagnosed with ovarian cancer in 2013 and subsequently sued J&J, claiming that the company failed to inform consumers like her about the dangers of talc. She died last fall at age 62 after her cancer returned.
In the wake of Fox’s death, her son, Marvin Salter, took over the case. On Feb. 22, a jury awarded Fox’s estate $10 million for compensatory damages and $62 million for punitive damages, according to the Associated Press (AP). Interestingly, both cases were tried in the same St. Louis courthouse.
No-Cost Evaluation
The attorneys at Nager, Romaine & Schneiberg are here to advocate on your behalf. If you or a loved one has — or you believe there is a risk of ovarian cancer — you may be entitled to compensation. Call the talcum powder lawsuit attorneys at Nager, Romaine & Schneiberg Co., LPA. We will evaluate the feasibility of a lawsuit and help determine whether you are entitled to compensation. Call NRS at 216-289-4740, or toll-free from Ohio at (855) GOT-HURT. You can also fill out our contact form for a free consultation.
http://www.nrsinjurylaw.com/blog/view/second-jj-talcum-powder-lawsuit-verdict-affirms-dangers-signals-more-litiga
-
Man files Xarelto Subdural Hematoma Lawsuit
May 5, 2016 | Miller Legal LLP
A man recently filed a personal injury lawsuit against drug manufacturers Bayer and the Janssen unit of Johnson & Johnson based on claims that he suffered severe and near-fatal injuries after using their drug Xarelto.
Thomas Coe filed his Xarelto lawsuit on March 16 in the U.S. District Court for the Eastern District of Louisiana. Here, Mr. Coe claims that he suffered a near-fatal subdural hematoma and bleeding on his brain less than one year after beginning to take Xarelto. He seeks to hold the drug makers responsible for his permanent injuries and charges them with failing to warn of serious Xarelto bleeding risks and the lack of a reversal agent.
Thomas Coe began to take Xarelto (rivaroxaban) in July 2013, and suffered a subdural hematoma less than one year later, in April 2014. WebMD states, “A subdural hematoma is a collection of blood outside the brain…the bleeding and increased pressure on the brain from a subdural hematoma can be life-threatening.”
While Mr. Coe admits that the risk of internal bleeding is present with all blood thinners, he claims that the makers of Xarelto failed to provide adequate warning of the severe risk of bleeding associated with Xarelto. Like other plaintiffs in Xarelto lawsuits, he also claims that the drug makers failed to alert patients that there is no reversal agent to stop Xarelto bleeding.
When it first came out in 2001, Xarelto was aggressively advertised as a superior alternative to another, older blood thinner called Coumadin (warfarin). Warfarin had gained a reputation as an inconvenient drug because patients are required to undergo regular blood monitoring to ensure a proper dose, and Xarelto users were not believed to need this. However, now many experts say that regular blood monitoring could have prevented many Xarelto bleeding events. Furthermore, when a patient taking Coumadin begins to bleed too much, clotting may be induced with a dose of Vitamin K. There is no such antidote for Xarelto bleeding, and some claim that if they had known this they may not have used the drug in the first place.
In his lawsuit, Mr. Coe claims, “Importantly, there is no antidote to Xarelto, unlike warfarin. Therefore, in the event of hemorrhagic complications, there is no available reversal agent. The original U.S. label approved when the drug was first marketed in the U.S. did not contain a warning regarding the lack of antidote, but instead only mentioned this important fact in the overdosage section.”
So many patients have filed Xarelto lawsuits that they have been centralized before a single judge in Louisiana for consolidated pretrial proceedings. Mr. Coe’s lawsuit will join the lawsuits filed by these plaintiffs, which currently number more than 4,500. It is expected that early trials will begin in this multidistrict litigation (MDL) in the spring of 2017.
If you or your loved one suffered serious or even fatal Xarelto internal bleeding, you may be entitled to compensation for your physical, emotional, and financial damages. For more information, pleasecontact us to schedule a free Xarelto lawsuit consultation with an experienced attorney.
http://www.xareltolawsuit.com/news/xarelto-subdural-hematoma-lawsuit/
-
What are Common Xarelto Bleeding Symptoms?
May 6, 2016 | Johnston Law Group
Common Xarelto bleeding symptoms may go unnoticed for some time, as is the case with certain internal bleeding wounds, or may be clearly indicated by intense pain and hemorrhaging. Taking certain drugs at the same time as Xarelto, such non-steroidal anti-inflammatory drugs or aspirin, increases the risk of bleeding.
Bleeding symptoms which may be related to Xarelto use include:
Bruising
Cool and sweaty skin
Headaches, confusion, dizziness or general weakness
Low blood pressure
Frequent nose bleeds or gum bleeding
Blood in urine
Intense pain
Coughing up blood
Vomiting, lethargy, seizure and unconsciousness
How Does Xarelto Cause Bleeding?
Because the drug is designed to stop the blood from clotting, there is a possibility that any injury – even a minor one – can be very dangerous. The blood thinner works by affecting specific proteins in the blood that normally start the clotting process and blocks them.
It can take as long as 24 hours for the drug to be flushed out of the system. Older adults have a more difficult time flushing the drug, and the anticoagulation effect lasts longer in their bodies. This puts seniors at increased risk for possibly fatal bleeds, especially if they fall or hit their heads.
Because there is no antidote, doctors have no way of immediately stopping the bleed, and the situation in the hospital can be dire. As the side effects mount, some doctors are growing wary of using it.
The drug can cause many types of bleeding, including internal and abdominal bleeding that may go unnoticed for some time. Xarelto users may begin to notice bleeding side effects such as bleeding from the rectum and severe hemorrhaging.
Patients who are going to have surgery must stop taking the drug at least 24 hours before the procedure to avoid complications. In addition, pregnant women may suffer hemorrhaging while taking Xarelto.
Compared to warfarin, Xarelto also causes more abdominal bleeding.
Black Box Warning For Spinal Bleeding
This blood thinner also has the U.S. Food and Drug Administration’s (FDA) most severe label warning for dangerous spinal bleeds called epidural or spinal hematomas. Hematomas are pools of blood that occur outside of blood vessels. Blood pooling in the spine can cause permanent paralysis.
People are at greater risk if they:
Use epidural catheters
Use other drugs that can affect the clotting process, such as NSAIDs or platelet inhibitors
Have a history of spinal trauma
Have a history of spinal surgery
The warning also cautions against any spinal procedures in patients who take Bayer’s drug.
Internal Bleeding Lawsuits
One of the biggest concerns with Xarelto is that it can cause irreversible bleeds that can be fatal. Trips to the hospital are costly and cause a good deal of emotional trauma for the patient and family members.
Victims filed the first U.S. lawsuits in June 2014.
Virginia Stuntebeck filed a lawsuit against Bayer in Philadelphia Courts after she suffered severe internal bleeding caused by the company’s blood thinner. In February 2013, she ended up in the hospital with severe gastrointestinal bleeding.
According to the complaint, Stuntebeck alleges that Bayer and Johnson & Johnson did not properly warn the public about the risks and should never have sold the drug.
“As the manufacturers and distributors of Xarelto, defendants knew or should have known that Xarelto use was associated with irreversible bleeds,” the complaint said.
A similar drug, Pradaxa, also caused irreversible bleeding and its manufacturer, Boehringer Ingelheim paid $650 million to settle thousands of cases. Meanwhile, Bayer maintains that the drug is safe.
http://masstortslaw.com/what-are-common-xarelto-bleeding-symptoms/
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Full Text of Stories Below
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Add recipients
Suggested